<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05017324</url>
  </required_header>
  <id_info>
    <org_study_id>AUR1-11-248</org_study_id>
    <secondary_id>T001018N</secondary_id>
    <secondary_id>2020-004084-10</secondary_id>
    <nct_id>NCT05017324</nct_id>
  </id_info>
  <brief_title>Sequencing Mycobacteria and Algorithm-determined Resistant Tuberculosis Treatment Trial</brief_title>
  <acronym>SMARTT</acronym>
  <official_title>Sequencing Mycobacteria and Algorithm-determined Resistant Tuberculosis Treatment Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universiteit Antwerpen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Aurum Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Stellenbosch</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of the Free State</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Free State Department of Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Universiteit Antwerpen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary aim of this pragmatic trial is to determine the effectiveness of a Whole Genome&#xD;
      Sequencing (WGS) Drug Sensitivity Testing (DST) strategy to guide individualised treatment of&#xD;
      rifampicin resistant tuberculosis (RR-TB) patients.&#xD;
&#xD;
      The primary objective is to determine the effectiveness of this WGS DST strategy in patients&#xD;
      diagnosed with RR-TB. We will additionally perform an exploratory health economics evaluation&#xD;
      of both arms, and will determine the feasibility of the WGS DST strategy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The trial will be a single blinded randomised controlled, pragmatic, medical device trial&#xD;
      evaluating a Whole Genome Sequencing (WGS) Drug Sensitivity Testing (DST) strategy to guide&#xD;
      individualised treatment of rifampicin resistant tuberculosis (RR-TB) patients. A total of&#xD;
      248 patients diagnosed with RR-TB in the South African Free State province will by randomised&#xD;
      to one of two trial arms. 124 patients will be assigned to the intervention arm, consisting&#xD;
      of a WGS DST strategy for diagnosing drug resistance profile and an algorithm-determined&#xD;
      individualised RR-TB treatment recommendation. 124 patients will be assigned to the control&#xD;
      arm where the diagnosis of Mtb drug resistance and individualisation of RR-TB treatment will&#xD;
      happen according to the Standard of Care (SOC) procedures.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 21, 2021</start_date>
  <completion_date type="Anticipated">January 2025</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized Controled Phase 4 pragmatic single blinded medical device trial.</intervention_model_description>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Effectiveness of a WGS DST strategy for individualisation of RR-TB treatment</measure>
    <time_frame>Day 0 to month 6 (6 months)</time_frame>
    <description>The effectiveness will be determined by the rate of change in time to positivity (TTP) over 6 months in the Mycobacterial Growth Indicator Tuber (MGIT) system [time from: Day 0 to Week 24].&#xD;
The effectiveness of the WGS DST strategy will be determined by the rate of change in TTP in liquid media MGIT cultures of sputum samples collected during the first 6 months of treatment. The TTP will be used to determine the change in mycobacterial load using a non-linear mixed effect time-to-event model that provides a longitudinal representation of mycobacterial load (measured as TTP in MGIT) at weeks 2, 3, 4, 5, 6, 7, 8, 12, 16, 20 and 24</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Health economic evaluation of a WGS DST strategy for individualization of RR-TB treatment</measure>
    <time_frame>Start of treatment to end of treatment (which may vary from 6 months to over 11 months)</time_frame>
    <description>The difference in total cost over the entire treatment period from a patients and health system perspective between a WGS strategy and SOC strategy will be assessed by comparing costing data collected at month 1 of treatment, month 6 of treatment and at the end of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact of WGS strategy for individualisation of RR-TB treatment on Health related Quality of Life (HRQOL)</measure>
    <time_frame>Start of treatment to end of treatment (which may vary from 6 months to over 11 months)</time_frame>
    <description>The difference in changes in health relates quality fo life will be assessed by comparing the change in HRQOL over time between patients randomised to the WGS and SOC strategies for individualisation of RR-TB treatment, using results of the EQ-5D-5L questionnaire collected at baseline, month 1, 2, 3, 4, 5, 6 and end of treatment.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">248</enrollment>
  <condition>Rifampicin Resistant Tuberculosis</condition>
  <condition>Drug-resistant Tuberculosis</condition>
  <condition>Multidrug Resistant Tuberculosis</condition>
  <condition>Pulmonary Tuberculoses</condition>
  <arm_group>
    <arm_group_label>WGS DST strategy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>WGS DST strategy for diagnosing the TB drug resistance profile and an individualised RR-TB treatment recommendation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of Care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Standard of care diagnosis of the drug resistance profile and individualised treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>WGS DST strategy</intervention_name>
    <description>WGS DST strategy for diagnosing the TB drug resistance profile and an algorithm-determined individualised RR-TB treatment recommendation</description>
    <arm_group_label>WGS DST strategy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosed with RR-TB&#xD;
&#xD;
          -  Diagnosed with pulmonary TB (PTB) or PTB plus extra-pulmonary TB (EPTB)&#xD;
&#xD;
          -  â‰¥18 years of age&#xD;
&#xD;
          -  Able to sign informed consent&#xD;
&#xD;
          -  Not on TB treatment at time of enrolment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients diagnosed EPTB without pulmonary involvement&#xD;
&#xD;
          -  Patients with TB Meningitis or TB of the bone.&#xD;
&#xD;
          -  Has any condition that, in the opinion of the investigator or physician, would&#xD;
             preclude provision of informed consent, make participation in the study unsafe,&#xD;
             complicate interpretation of study outcome data, interfere with achieving the study&#xD;
             objectives or compromise patient safety.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gavin Churchyard, PhD, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Aurum Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Annelies Van Rie, PhD, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universiteit Antwerpen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rob M Warren, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stellenbosch University, MRC</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Salome Charalambous, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Aurum Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Elise De Vos, MSc</last_name>
    <phone>0032477715350</phone>
    <email>elise.devos@uantwerpen.be</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Annelies Van Rie, PhD, MD</last_name>
    <email>annelies.vanrie@uantwerpen.be</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Free State Department of Health Clinics</name>
      <address>
        <city>Bloemfontein</city>
        <state>Free State</state>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Salome Charalambous, PhD</last_name>
      <phone>+27 10 590 1389</phone>
      <email>SCharalambous@auruminstitute.org</email>
    </contact>
  </location>
  <location_countries>
    <country>South Africa</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>April 22, 2021</study_first_submitted>
  <study_first_submitted_qc>August 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 23, 2021</study_first_posted>
  <last_update_submitted>October 14, 2021</last_update_submitted>
  <last_update_submitted_qc>October 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universiteit Antwerpen</investigator_affiliation>
    <investigator_full_name>Annelies Van Rie</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Whole Genome Sequencing</keyword>
  <keyword>Drug Resistant Tuberculosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tuberculosis</mesh_term>
    <mesh_term>Tuberculosis, Pulmonary</mesh_term>
    <mesh_term>Tuberculosis, Multidrug-Resistant</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The analysable individual patient data (IPD) will be made available, including WGS data (to be published on the European Nucleotide Archive (ENA)) and de-identified clinical and demographic IPD. This ensures an adit trial for summary results reporting, enables re-analyses of trial data and the possibility for combining the data with others for novel investigations.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>From publication of the results of the primary up to 5 years thereafter</ipd_time_frame>
    <ipd_access_criteria>WGS: available on European Nucleotide Archive (ENA) Other data: access will be provided to researchers who have obtained Institutional Review Board (IRB) approval for analyses</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

